Delivery Order SPE2D021DA002-SPE2D326F3742

The Defense Logistics Agency's Medical Supply Chain division awarded a delivery order valued at $3,210.30 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Procainamide 1 gram/10 mL vials. The contract, issued on January 13, 2026, with an ultimate completion date of January 14, 2026, operates under a firm fixed-price structure with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded in November 2025 with a $499.999 billion ceiling value and completion date of December 31, 2036.

DMS Pharmaceutical Group serves as a critical regional pharmaceutical supplier within the DoD's broader $30.3 billion PPV-G GEN V acquisition strategy, authorized to provide branded and generic prescription medications, over-the-counter drugs, biologics, and medical consumables to support military healthcare facilities worldwide. The company's demonstrated performance across numerous delivery orders and its comprehensive product portfolio—spanning oncology treatments, vaccines, emergency medications, and specialty pharmaceuticals—positions it as a key vendor within the federal pharmaceutical supply chain. No subcontractors are identified in the award documentation.